Loss of Commonly Mutated Gene in Prostate Tumors May Be Potential Biomarker for Targeted Treatment

Loss of Commonly Mutated Gene in Prostate Tumors May Be Potential Biomarker for Targeted Treatment
A new research study found that the loss of CHD1, one of the most commonly mutated genes in prostate tumors, may be a potential biomarker for targeted prostate cancer therapy. In the study, “Loss of CHD1 causes DNA repair defects and enhances prostate cancer therapeutic responsiveness,” published in EMBO Reports, researchers showed that CDH1 is involved in DNA

Knowledge is power when living with prostate cancer.

Get access to the web’s leading Prostate Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *